Adherence to therapy with oral antineoplastic agents.

By A. Partridge, J. Avorn, Philip S. Wang, E. Winer. Journal of the National Cancer Institute, 2002

618 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010, background): “As adherence declines, pill counts become even less accurate.(12,13) Moreover, patients who are persistently noncompliant tend to take their medication on the day before they visit their physician, thereby giving a false impression of adherence when drug levels are measured.”